These observations provide credence to the view that targeting integrin αvβ8 activation of latent TGFβ with specific anti–integrin β8 antibodies (Takasaka et al. 2018, Dodagatta-Marri et al. 2021) or small molecules (Reichart et al. 2019) may be more efficacious than blocking the free ligand and less likely to instigate systemic adverse effects away from the tumor site. This evidence concerns the gene TGFB1 and neoplasm.